Project Grant R15CA304777
Award Date
7/7/25
Completion Date
6/30/28
Dollars Obligated
$550K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Tennessee, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $131,300 to Middle Tennessee State University to develop a novel dual inhibitor for the treatment of MYCN-amplified neuroblastoma. The key objectives are to: Identify the genes regulated by the N-MYC oncogene and its cofactors WDR5 and G9A, and determine how combined inhibition of these cofactors impacts N-MYC-dependent transcription. Pursue the identification and screening of potential...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to Emory University provides $489,527 over a 5-year period starting January 1, 2025. The project aims to enhance the understanding of genetic variants in the SMARCB1 gene and their functional consequences in cancers characterized by SMARCB1 deficiency, which affect children, adolescents, and young adults. The research will focus on assessing how SMARCB1 missense mutations...
This $377,870 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development and validation of novel synthetic transcriptional repressors (STRs) capable of directly inhibiting the oncogenic transcription factor MYC. The grant aims to: 1) Optimize STR structures for high-affinity and specific binding to MYC target DNA sequences, 2) Enhance cellular and pharmacologic delivery of STRs while mapping their effects on epigenetic and...
The National Cancer Institute (NCI) awarded a $581,381 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Sloan-Kettering Institute for Cancer Research. The 5-year grant, effective June 5, 2025, will fund research to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance in cancer. The key products of this research will be a better understanding of DNA damage repair pathways and how they contribute...
The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) worth $718,113 to St. Jude Children's Research Hospital Inc. on January 15, 2025. The grant supports research aimed at understanding the mechanisms by which the MYC oncogenes interact with core regulatory circuitry transcription factors (CRC TFs) and epigenetic modifiers, such as histone deacetylases (HDAC) and histone lysine demethylase 4 family (KDM4), to promote neuroblastoma...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $557,418 to The Trustees of Columbia University in the City of New York to conduct research on targeting SMARCA2 in SMARCA4-deficient lung cancers. The research aims to assess the effects of SMARCA2 degradation on SMARCA4-deficient lung cancer progression, elucidate the mechanisms underlying the relationship between SMARCA2 and SMARCA4, and develop effective combinatorial approaches...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $164,628 to President and Fellows of Harvard College to conduct research on defining the roles of sequence-non-specific DNA-binding domains in mammalian SWI/SNF chromatin remodeling complexes. The research aims to elucidate how these DNA-binding domains contribute to proper assembly, integrity, catalytic activity, nucleosome remodeling, genomic targeting, and DNA accessibility generation...
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Research Manpower program (CFDA 93.398) to St. Jude Children's Research Hospital Inc. in the amount of $226,608 to investigate the mechanism by which a gene essential for rhabdoid tumor viability regulates chromatin function. The project aims to provide novel insights into chromatin-mediated control of transcription, the interplay between the SWI/SNF and Polycomb chromatin remodeling complexes disrupted in cancer, and...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Research Manpower (CFDA 93.398) program, provides $377,102 to The Johns Hopkins University to investigate the effects of MYC gene expression on protein translation dynamics in cancer. The research aims to: 1) examine how MYC expression impacts protein translation processes, 2a) assess how MYC affects ribosome collision frequency and sensitivity to translation stress, and 2b) determine if translation...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research to define key components of the PRMT5 axis that impair cell viability upon PRMT5 inhibition and identify pathways that can restore viability in MTAP-deleted cancer cells. The $442,089 award to Yale University will leverage a genome-scale CRISPR activation platform to identify genes that modulate sensitivity to PRMT5 pathway inhibition. The research aims to...